Chief Research and Development Officer · NEKTAR THERAPEUTICS (NKTR)

Stephen Doberstein

A named executive officer of NEKTAR THERAPEUTICS in every fiscal year CompBrief holds from FY2016 to FY2018. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2018

$4,811,856

Salary $600,000Stock awards $1,748,824

FY2017: $7,698,950

4th of 5 named executive officers at Nektar Therapeutics by FY2018 total.

5 named officers on file for NEKTAR THERAPEUTICS, FY2018

Stephen Doberstein’s pay file — $29

  • 3 fiscal years of pay, line by line
  • 4 equity grants, each cited to its filing
  • NKTR’s disclosed peer group of 19 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how NEKTAR THERAPEUTICS’s whole pay program stands against its peers

  • NEKTAR THERAPEUTICS’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on NKTR→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 30, 2019 (DEF 14A).

Free

Get Stephen Doberstein’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Stephen Doberstein compensation by year

NEKTAR THERAPEUTICS Summary Compensation Table · all 3 fiscal years held
In US dollars, as NEKTAR THERAPEUTICS reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2016FY2017FY2018
Salary$508,200$529,084$600,000
Bonus$0$0$0
Stock awards$428,396$2,958,794$1,748,824
Option awards$504,526$3,672,084$1,965,476
Non-equity incentive$266,805$525,000$480,000
Pension and deferred compensation$0$0$0
All other$12,806$13,988$17,556
Total$1,720,733$7,698,950$4,811,856

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: NEKTAR THERAPEUTICS DEF 14A filed April 30, 2019, accession 0001193125-19-129488, and prior-year filings. Open the filing on EDGAR.

How this page was built: the NEKTAR THERAPEUTICS filed document, accession 0001193125-19-129488. Every figure is read from that document and cited to the page and table it appears in. Filed April 30, 2019.

$1.7M
$7.7M
$4.8M
FY16
FY17
FY18
SalaryNon-equity incentiveStock awardsOption awardsAll other

NEKTAR THERAPEUTICS’s named executive officers, FY2018

as the company reported each
Named executive officerRoleFY2018 total
Howard RobinPresident and Chief Executive Officer$13,330,667
Jillian ThomsenSenior Vice President Finance and Chief Accounting Officer$6,233,595
Gil LabrucherieSenior Vice President and Chief Financial Officer$5,733,928
Stephen Doberstein · this pageChief Research and Development Officer$4,811,856
Maninder HoraSenior Vice President Pharmaceutical Development and Chief Technical Operations Officer$3,839,442

The full NEKTAR THERAPEUTICS compensation record

free company brief

This page is one person within NEKTAR THERAPEUTICS's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the NEKTAR THERAPEUTICS proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are NEKTAR THERAPEUTICS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Stephen Doberstein's compensation dossier · One-time report. No refunds.